Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-20 DOI:10.1080/14737167.2025.2465445

Marcello Vaccaro, Giacomo Polito, Gabriele Bagaglini, Maurizio Capuozzo, Roberto Langella, Eduardo Nava, Andrea Zovi, Francesco Ferrara

{"title":"Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities.","authors":"Marcello Vaccaro, Giacomo Polito, Gabriele Bagaglini, Maurizio Capuozzo, Roberto Langella, Eduardo Nava, Andrea Zovi, Francesco Ferrara","doi":"10.1080/14737167.2025.2465445","DOIUrl":null,"url":null,"abstract":"Background: Biosimilar drugs represent a valuable opportunity for healthcare systems worldwide as they offer substantial cost savings. This retrospective observational study aimed to assess the current prescribing trend in order to raise awareness among physicians for more appropriate prescribing.Research design and methods: A study was conducted to assess the use of major biologic drugs across different therapeutic areas within two Italian healthcare entities. Usage and cost data were obtained from company databases. In addition, a comparison with 2021 data was performed to identify any increases in biosimilar drug utilization during 2022.Results: The analysis for 2022 revealed that the majority of studied active ingredients have been administered as biosimilar drugs, with percentages close to 100%, except for a few exceptions. In particular, resistance remained in the prescription of biosimilar adalimumab (73.8%) and etanercept (73.3%) in Asl Napoli 3 Sud, erythropoietin (69.5%) and rituximab (72.8%) in Policlinico Umberto I.Conclusions: A comparison between 2021 and 2022 highlighted the increasing adoption of biosimilar drugs. This positive trend suggested the potential for full utilization in the near future, benefiting significantly the National Health System and the public, ensuring a healthcare approach that is effective and sustainable.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-7"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2465445","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Biosimilar drugs represent a valuable opportunity for healthcare systems worldwide as they offer substantial cost savings. This retrospective observational study aimed to assess the current prescribing trend in order to raise awareness among physicians for more appropriate prescribing.

Research design and methods: A study was conducted to assess the use of major biologic drugs across different therapeutic areas within two Italian healthcare entities. Usage and cost data were obtained from company databases. In addition, a comparison with 2021 data was performed to identify any increases in biosimilar drug utilization during 2022.

Results: The analysis for 2022 revealed that the majority of studied active ingredients have been administered as biosimilar drugs, with percentages close to 100%, except for a few exceptions. In particular, resistance remained in the prescription of biosimilar adalimumab (73.8%) and etanercept (73.3%) in Asl Napoli 3 Sud, erythropoietin (69.5%) and rituximab (72.8%) in Policlinico Umberto I.

Conclusions: A comparison between 2021 and 2022 highlighted the increasing adoption of biosimilar drugs. This positive trend suggested the potential for full utilization in the near future, benefiting significantly the National Health System and the public, ensuring a healthcare approach that is effective and sustainable.

查看原文本刊更多论文

2022 年意大利生物药品消耗量评估：两家医疗机构的对比分析。

背景：生物仿制药为全球医疗保健系统提供了一个宝贵的机会，因为它们提供了大量的成本节约。本回顾性观察性研究旨在评估当前的处方趋势，以提高医生对更适当的处方的认识。研究设计和方法：进行了一项研究，以评估意大利两个医疗保健实体在不同治疗领域中主要生物药物的使用情况。使用和成本数据来自公司数据库。此外，还与2021年的数据进行了比较，以确定2022年期间生物类似药使用的任何增加。结果：2022年的分析显示，除少数例外情况外，大多数研究的活性成分已作为生物仿制药给药，百分比接近100%。特别是，在那不勒斯3南部地区，阿达木单抗（73.8%）和依那西普（73.3%）的生物仿制药处方中仍存在耐药性，在Policlinico Umberto i地区，促红细胞生成素（69.5%）和利妥昔单抗（72.8%）的耐药性仍然存在。结论：2021年和2022年的比较突出了生物仿制药的使用增加。这一积极趋势表明，在不久的将来有可能充分利用，使国家卫生系统和公众大大受益，确保有效和可持续的卫生保健方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.